Zealand Pharma Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Zealand Pharma şirketinin kazançları yıllık ortalama -7.5% oranında azalırken, Biotechs sektörünün kazançları yıllık 7.7% oranında artan oldu. Gelirler yıllık ortalama 13.7% oranında artan oldu.

Anahtar bilgiler

-7.5%

Kazanç büyüme oranı

3.8%

EPS büyüme oranı

Biotechs Sektör Büyümesi	18.7%
Gelir büyüme oranı	13.7%
Özkaynak getirisi	-11.8%
Net Marj	-1,369.3%
Sonraki Kazanç Güncellemesi	20 Feb 2025

Yakın geçmiş performans güncellemeleri

Recent updates

Zealand Pharma A/S (CPH:ZEAL) Just Released Its Second-Quarter Earnings: Here's What Analysts Think

Aug 18

Auditors Are Concerned About Zealand Pharma (CPH:ZEAL)

Mar 17

Here's Why We're Watching Zealand Pharma's (CPH:ZEAL) Cash Burn Situation

Oct 03

Downgrade: Here's How Analysts See Zealand Pharma A/S (CPH:ZEAL) Performing In The Near Term

Aug 14

Gelir ve Gider Dağılımı

Zealand Pharma nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

CPSE:ZEAL Gelir, gider ve kazançlar (DKK Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri	Ar-Ge Giderleri
30 Sep 24	77	-1,053	314	171
30 Jun 24	368	-712	270	105
31 Mar 24	344	-739	244	49
31 Dec 23	343	-704	216	0
30 Sep 23	343	-760	205	42
30 Jun 23	92	-986	215	-9
31 Mar 23	107	-1,064	241	-13
31 Dec 22	104	-966	258	0
30 Sep 22	93	-855	273	612
30 Jun 22	104	-845	286	606
31 Mar 22	114	-608	231	602
31 Dec 21	109	-755	298	582
30 Sep 21	158	-925	416	595
30 Jun 21	161	-1,012	480	595
31 Mar 21	347	-909	575	574
31 Dec 20	192	-669	222	596
30 Sep 20	301	-660	300	612
30 Jun 20	255	-545	178	596
31 Mar 20	54	-624	79	605
31 Dec 19	41	-572	68	561
30 Sep 19	43	-508	68	522
30 Jun 19	33	524	62	486
31 Mar 19	28	551	50	471
31 Dec 18	38	581	44	438
30 Sep 18	35	601	49	394
30 Jun 18	74	-361	47	375
31 Mar 18	68	-346	52	347
31 Dec 17	136	-274	47	324
30 Sep 17	306	-112	58	293
30 Jun 17	307	-100	55	274
31 Mar 17	306	-102	61	259
31 Dec 16	231	-157	59	262
30 Sep 16	221	-138	51	243
30 Jun 16	189	-158	55	237
31 Mar 16	188	-139	48	224
31 Dec 15	188	-114	48	212
30 Sep 15	27	-246	48	217
30 Jun 15	78	-178	44	212
31 Mar 15	75	-147	39	195
31 Dec 14	154	-65	40	180
30 Sep 14	151	-47	31	160
30 Jun 14	95	-98	33	151
31 Mar 14	92	-97	35	147
31 Dec 13	7	-184	34	164

Kaliteli Kazançlar: ZEAL şu anda kârlı değil.

Büyüyen Kar Marjı: ZEAL şu anda kârlı değil.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: ZEAL kârlı değildir ve zararlar son 5 yılda yılda 7.5% oranında artmıştır.

Büyüme Hızlandırma: ZEAL 'un son bir yıldaki kazanç büyümesinin 5 yıllık ortalamasıyla karşılaştırılması mümkün değil çünkü şu anda kârlı değil

Kazançlar vs. Sektör: ZEAL kârlı olmadığından, geçmiş yıl kazanç büyümesinin Biotechs sektörüyle ( -20.8% ) karşılaştırılması zorlaşıyor.

Özkaynak Getirisi

Yüksek ROE: ZEAL hissesi şu anda kârlı olmadığından negatif Özsermaye Getirisi'ne ( -11.85% ) sahiptir.

Zealand Pharma Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Zealand Pharma A/S to Report Q1, 2025 Results on May 08, 2025

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Zealand Pharma A/S to Report Q1, 2024 Results on May 16, 2024

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Full year 2021 earnings: Revenues in line with analyst expectations

Recent updates

Employee Representative Director recently sold kr.1.3m worth of stock

Forecast to breakeven in 2025

Analyst Forecasts For Zealand Pharma A/S (CPH:ZEAL) Are Surging Higher

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Zealand Pharma A/S to Report Q1, 2025 Results on May 08, 2025

Consensus EPS estimates fall by 14%

Zealand Pharma Provides U.S. Regulatory Update on Dasiglucagon in Congenital Hyperinsulinism

Insufficient new directors

Rock star Growth Puts Zealand Pharma (CPH:ZEAL) In A Position To Use Debt

President & CEO recently sold kr.31m worth of stock

Consensus revenue estimates fall by 11%

Things Look Grim For Zealand Pharma A/S (CPH:ZEAL) After Today's Downgrade

Zealand Pharma A/S (CPH:ZEAL) Just Released Its Second-Quarter Earnings: Here's What Analysts Think

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates fall by 40%

Zealand Pharma A/S Appoints Eric Cox as Chief Commercial Officer, Effective August 5, 2024

Zealand Pharma A/S has filed a Follow-on Equity Offering in the amount of DKK 6.257 billion.

Zealand Pharma A/S Announces Positive Topline Results from the Phase 1B 16-Week Multiple Ascending Dose Clinical Trial with Long-Acting Amylin Analog Petrelintide

Zealand Pharma A/S Announces Boehringer Ingelheim Will Present Positive Results from Phase 2 Trial with Survivalodutide in MASH at EASL

Zealand Pharma Announces Topline Results from the Mechanistic Investigator-Led Dream Trial with Low Doses of GLP-1/GLP-2 Receptor Dual Agonist Dapiglutide

Zealand Pharma A/S Approves Appointments to the Board

Zealand Pharma A/S Announces Board Changes

Zealand Pharma A/S Announces Boehringer Ingelheim Survodutide Phase 2 Trial Shows 83% of Adults Treated a Statistically Significant Improvement of Metabolic Dysfunction-Associated Steatohepatitis

Zealand Pharma A/S, Annual General Meeting, Mar 20, 2024

Zealand Pharma A/S has completed a Follow-on Equity Offering in the amount of DKK 1.45362 billion.

Zealand Pharma A/S has filed a Follow-on Equity Offering in the amount of DKK 1.45362 billion.

Zealand Pharma A/S Appoints Enrique Conterno and Elaine Sullivan as Board Observers

Zealand Pharma A/S to Report Q1, 2024 Results on May 16, 2024

Boehringer Ingelheim and Zealand Pharma A/S Announces Initiation of Three Phase III Trials

Zealand Pharma A/S Announces Designation of Priority Review by the US FDA for Dasiglucagon in Congital Hyperinsulinism

Zealand Pharma A/S Announces Positive Results from Part 1 of Multiple Ascending Dosing Trial with Amylin Analog ZP8396

Zealand Pharma Submits Marketing Authorization Application for Dasiglucagon for Treatment of Severe Hypoglycemia in Diabetes to the European Medicines Agency

Boehringer Ingelheim and Zealand Pharma A/S Announces Phase II Trial Showed 14.9% Weight Loss in People Living with Obesity or Unveil

Zealand Pharma A/S has completed a Follow-on Equity Offering in the amount of DKK 786.05 million.

Zealand Pharma A/S Announces Positive Results from Phase 3 Trial of Glepaglutide in Patients with Short Bowel Syndrome (Ease 1)

Zealand Pharma Presents Data from Phase 3 Trial of Dasiglucagon in Congenital Hyperinsulinism At the 60Th Annual Espe Meeting

Zealand Pharma A/S Announces Chief Financial Officer Changes

Zealand Pharma A/S Revises Revenue Guidance for the Full Year of 2022

Zealand Pharma Announces Voluntary Delisting of American Depositary Shares from the Nasdaq Global Select Market

Zealand Pharma A/S Presents Data from Phase 1 Trial of Dapiglutide and to Move into Phase 2 Trial for Obesity

Zealand Pharma Announces Appoints David M. Kendall, as Chief Medical Officer

Insufficient new directors

Consensus forecasts updated

Zealand Pharma A/S Announces Positive Top-Line Results from Its Second Phase 3 Clinical Trial of Dasiglucagon in Pediatric Patients with Congenital Hyperinsulinism

Zealand Pharma A/S (CPSE:ZEAL) entered into an agreement to acquire V-Go® Insulin Delivery Device from Zealand Pharma for $10 million.

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Insufficient new directors

Price target decreased to kr.229

Zealand Pharma Announces CEO Changes

Auditors Are Concerned About Zealand Pharma (CPH:ZEAL)

Full year 2021 earnings: Revenues in line with analyst expectations

Consensus forecasts updated

Zealand Pharma A/S Announces Completion of Patient Enrollment in the Second Phase 3-Trial, 17103 in Children with Congenital Hyperinsulinism

Zealand Pharma Completes Enrollment in Ease-SBS 1 Phase 3 Trial Assessing Glepaglutide in Patients with Short Bowel Syndrome

Zealand Pharma Announces Enrollment of Last Patient Needed for Interim Analysis of EASE-SBS 1 Phase 3 Trial Assessing Glepaglutide in Patients with Short Bowel Syndrome

Consensus forecasts updated

Zealand Pharma A/S announced that it expects to receive $200 million in funding from Oberland Capital Management LLC

Zealand Pharma Announces Successful Outcome of Phase 1B Clinical Trial with GLP1-GLP2 Dual Receptor Agonist, Dapiglutide

Price target decreased to kr.228

Third quarter 2021 earnings released: kr.4.61 loss per share (vs kr.5.76 loss in 3Q 2020)

Price target decreased to kr.236

Here's Why We're Watching Zealand Pharma's (CPH:ZEAL) Cash Burn Situation

Zealand Pharma A/S Presents Data At 2021 ESPEN Virtual Congress Demonstrating Dose-Dependent Effects of Glepaglutide in Both Small and Large Intestines of Animal Models –in Contrast to Short-Acting GLP-2

Employee Elected Director Gertrud Rasmussen has left the company

Employee Elected Director Gertrud Rasmussen has left the company

Zealand Pharma Announces First Patient Dosed in EASE-SBS 4 Phase 3b Trial Assessing Glepaglutide in Patients with Short Bowel Syndrome

Downgrade: Here's How Analysts See Zealand Pharma A/S (CPH:ZEAL) Performing In The Near Term

Consensus EPS estimates fall to -kr.28.75

Protagonist Therapeutics, Inc Announces Resolution of Contract Dispute with Zealand Pharma